methylprednisolone oral / Generic mfg. - LARVOL DELTA

The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: F. Johannes Plate | N=100 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Immunology • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Rheumatology

Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis. (PubMed, Dermatol Reports) - "Tildrakizumab was discontinued, and the patient was treated with topical corticosteroids and low-dose oral methylprednisolone, achieving complete hair regrowth within 6 months. Psoriasis subsequently recurred, and treatment was successfully switched to bimekizumab, with sustained remission and no adverse events...The temporal correlation, lack of confounding risk factors, and resolution upon drug withdrawal suggest a causal relationship. This case expands the spectrum of paradoxical reactions (PRs) to biologic therapies and highlights the need for vigilance regarding autoimmune manifestations during interleukin (IL)-23 inhibition."

Journal • Alopecia • Dermatology • Immunology • Psoriasis

A Phase 1 Study of Ruxolitinib, Lenalidomide and Steroids for Patients with Relapsed/Refractory Multiple Myeloma. (PubMed, Clin Cancer Res) - "This study provides the basis for studying the addition of JAK inhibitors to improve the efficacy of immunomodulatory agents with steroids for treating myeloma patients but perhaps can also be expanded for treating other cancer patients that are refractory to this class of drugs."

Clinical • Journal • P1 data • Hematological Disorders • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Multiple Myeloma • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

A critically ill adolescent with EBV-associated hemophagocytic lymphohistiocytosis-induced hyperinflammatory shock: a case report and literature review. (PubMed, Front Immunol) - "The patient was discharged on a tapering regimen of oral methylprednisolone and achieved complete recovery without relapse during follow-up. This case suggests that rapidly progressive and significant leukopenia and thrombocytopenia are key early indicators for distinguishing EBV-HLH from sepsis alone. Early recognition of EBV-HLH and timely initiation of combined corticosteroid and antiviral therapy can effectively control cytokine storm and improve clinical outcomes in patients with favorable treatment responses, providing valuable clinical insights for managing similar severe cases."

Journal • Cardiovascular • Critical care • Epstein-Barr Virus Infections • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Hypotension • Immunology • Infectious Disease • Leukopenia • Rare Diseases • Septic Shock • Thrombocytopenia • IL2 • ISG20

Idiopathic Hypertrophic Pachymeningitis with Elevated Anti-Thyroglobulin Antibodies-A Case Report. (PubMed, Reports (MDPI)) - "Symptoms repeatedly improved with oral methylprednisolone and recurred on taper; adverse effects were mild and manageable... IHPM may exhibit a dissociation between clinical response and radiologic course. Persistently elevated anti-Tg after thyroidectomy can coexist with IHPM and may signal ongoing autoimmunity rather than active cancer."

Journal • CNS Disorders • Endocrine Disorders • Hypotension • Immunology • Infectious Disease • Oncology • Otorhinolaryngology • Pain • Vertigo

Localized palmar mycosis fungoides: A case report. (PubMed, Medicine (Baltimore)) - "This case highlights the diagnostic pitfalls of palmar MF and underscores the necessity of early biopsy in patients with persistent, treatment-resistant palm dermatoses. Raising clinical awareness of this rare entity may prevent misdiagnosis, facilitate timely therapy, and ultimately improve patient prognosis."

Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Oncology • Psoriasis • T Cell Non-Hodgkin Lymphoma

Ecotoxicological impact and biological interactions of cathinone-derived psychoactive substances through quantitative structure-activity relationship (QSAR) based predictive modelling. (PubMed, Sci Total Environ) - "This study evaluates ecotoxicological impact and biological interactions of Cathinone (Cath), Methcathinone (MC), Amfebutamone (TBCP), α-Pyrrolidinovalerophenone (α-PVP), Methylone (MDMC), and Methylenedioxy pyrovalerone (MDPV) using QSAR and AOP-based predictive modelling...The key interacting genes of six cathinone compounds were identified, and corresponding pathway mapping and molecular docking were done. Molecular docking revealed strong MDPV-protein interactions, suggesting significant biological and toxicological effects."

Journal

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Assiut University | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Oral Fluid Concentrations and Pharmacological Effects of Clephedrone and Methylone in Humans. (PubMed, Int J Mol Sci) - "However, clephedrone exhibited a delayed onset and peak of effects compared with methylone, indicating a clinically relevant pharmacokinetic difference. Both substances were detected in oral fluid, with peak concentrations occurring later following clephedrone administration, consistent with its delayed pharmacodynamic profile."

Journal • Observational data

A comparative study of portoenterostomy and choledochojejunostomy in New Zealand rabbits under immunosuppression. (PubMed, Front Surg) - "Postoperatively, all rabbits were administered oral methylprednisolone and cyclosporine A. Four rabbits from each group were sacrificed on postoperative days 30, 60, and 90. Pathological observations indicated good healing outcomes within 1 to 3 months postoperatively, despite the presence of inflammation and scar formation. The study demonstrates that small portoenterostomy performed under immunosuppressive therapy is a safe, simple, and technically feasible surgical approach."

Journal • Preclinical • Biliary Cancer • Cholangiocarcinoma • Inflammation • Nephrology • Oncology • Renal Disease • Solid Tumor • Transplantation

Consecutive presumed endogenous candida endophthalmitis and presumed cytomegalovirus uveitis in an immunocompromised patient: a case report. (PubMed, J Med Case Rep) - "This case highlights the risk of severe, sequential intraocular infections in immunocompromised patients and the importance of astute clinical observation and high index of suspicion. Favorable visual outcomes can be achieved through prompt, tailored treatment and long-term follow-up."

Journal • Cytomegalovirus Infection • Immunology • Infectious Disease • Inflammatory Arthritis • Ocular Infections • Ocular Inflammation • Ophthalmology • Rheumatoid Arthritis • Rheumatology • Uveitis

A Rare Case of Polyserositis With Elevated Serum Cancer Antigen (CA)-125 in Systemic Lupus Erythematosus: A Case Report of Pseudo-Pseudo Meigs Syndrome. (PubMed, Cureus) - "Her symptoms were well-controlled with prednisolone and hydroxychloroquine. She presented with a history of shortness of breath, diffuse abdominal pain, and abdominal distension...The patient was treated initially with furosemide without improvement. After confirming the diagnosis, methylprednisolone and oral prednisone were then administered with a favorable prognosis...Early recognition is crucial to minimize the need for unnecessary invasive procedures. The goal is to initiate the appropriate management as early as possible to optimize patient outcomes."

Journal • Immunology • Inflammatory Arthritis • Lupus • Multiple Sclerosis • Oncology • Ovarian Cancer • Pain • Respiratory Diseases • Solid Tumor • Systemic Lupus Erythematosus • MUC16

A very rare cause of oliguric acute kidney disease: crescentic C3 glomerulopathy. (PubMed, Oxf Med Case Reports) - "The patient was successfully treated with oral methylprednisolone and 6 doses of monthly parenteral cyclophosphamide. Monoclonal gammopathy and genetic factor H defects should be investigated to determine the underlying etiology in C3G patients. Monthly cycles of cyclophosphamide infusion (a total of 6 cycles) are beneficial for these patients."

Journal • Acute Kidney Injury • ANCA Vasculitis • Complement-mediated Rare Disorders • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Monoclonal Gammopathy • Nephrology • Renal Disease • Vasculitis

Idiopathic Multicentric Castleman Disease With Severe Eosinophilia and Diffuse Centrilobular Nodule-A Rare Case Report. (PubMed, Case Rep Hematol) - "The patient declined cytotoxic chemotherapy and was treated with oral methylprednisolone (40 mg/day), which was gradually tapered to 10 mg/day...This case highlights a rare presentation of iMCD with eosinophilia and pulmonary involvement, emphasizing the importance of early recognition and timely corticosteroid therapy. Our report adds to the limited data on iMCD with eosinophilia and may help inform future clinical management."

Journal • Cough • Eosinophilia • Infectious Disease • Oncology • Pulmonary Disease • Rare Diseases • Respiratory Diseases • CXCL8 • IL1B • IL6 • TNFA

Sequential, Multifocal, and Delayed Avascular Necrosis of All Four Major Joints From Hips to Shoulders Following Corticosteroid Therapy. (PubMed, Cureus) - "We describe a 59-year-old male patient who received a tapered regimen of oral methylprednisolone for facial palsy in 2012...This case illustrates delayed, multifocal, steroid-induced osteonecrosis progressively involving both hips and shoulders over more than a decade. This clinical scenario raises an important consideration: whether patients undergoing corticosteroid therapy should receive routine imaging of major joints to facilitate early detection of osteonecrosis and enable timely interventions, such as core decompression, that may delay or prevent progression to end-stage joint destruction requiring arthroplasty."

Journal • CNS Disorders • Orthopedics • Pain

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P=N/A | N=30 | Recruiting | Sponsor: Assiut University | Active, not recruiting ➔ Recruiting | Trial primary completion date: Sep 2025 ➔ Dec 2025

Enrollment open • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

From Euphoria to Cardiac Stress: Role of Oxidative Stress on the Cardiotoxicity of Methylone and 3,4-DMMC. (PubMed, Toxics) - "Synthetic cathinones (SCs), commonly referred to as "bath salts", are a class of novel psychoactive substances (NPSs) that elicit amphetamine-like effects and severe cardiovascular outcomes, including myocardial infarction and sudden cardiac death...Intracellular reactive oxygen/nitrogen species (ROS/RNS) were quantified by fluorescence, and antioxidant effects were evaluated using ascorbic acid, N-acetylcysteine, and Trolox...Taken together, these findings demonstrate for the first time that methylone and 3,4-DMMC exert cardiotoxic effects in vitro, with oxidative stress as a key contributor. The protective effect of ascorbic acid highlights its potential as a therapeutic candidate against SC-induced cardiac injury."

Journal • Cardiovascular • Myocardial Infarction

IMPACT-2: An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD (clinicaltrials.gov) - P2 | N=62 | Completed | Sponsor: Transcend Therapeutics | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

IMPACT-EXT: An Evaluation of the Long-term Efficacy and Safety of Methylone for the Treatment of PTSD (clinicaltrials.gov) - P2 | N=44 | Completed | Sponsor: Transcend Therapeutics | Enrolling by invitation ➔ Completed | N=150 ➔ 44 | Trial completion date: May 2027 ➔ Oct 2025 | Trial primary completion date: May 2027 ➔ Oct 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

DRESS To Kill: A Case of Severe Drug Reaction Eosinophilia Systemic Symptoms Recurrence with Second-Line anti-Tuberculosis Medication in a 44-Year-Old Asian Woman (APSR 2025) - "Case Report : We report a presentation of DRESS in a 44-year-old Asian female with Multi-Drug Rifampicin Resistant Tuberculosis (MDR-TB)...Cessation of anti-TB drugs and initiation of oral methylprednisolone resulted in clinical improvement and was discharged on a corticosteroid regimen over 14 days. Rechallenging treatment using a graded protocol with second- line MDR-TB agents (Linezolid, Delamanid, Cycloserine, and Levofloxacin) caused recurrence of symptoms, including rash with desquamation, eosinophilia, and elevated liver enzymes...Prednisone was carefully tapered over six months...Knowledge, early recognition, early cessation, prompt management are of important to minimize morbidity and mortality. Furthermore, outpatient follow up is vital to prevent relapses and long-term sequelae including organ damage, infections, and mental health complications."

Clinical • Autoimmune Hepatitis • Eosinophilia • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Respiratory Diseases • Tuberculosis

A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone (ASH 2023) - "Initially, subjects received oral RUX 15 mg twice daily and oral methylprednisolone 40 mg every other day. This three-drug combination is well tolerated and is able to extend the benefit of RUX-based treatment for these patients. The promising results from this phase 1 clinical trial demonstrate a potential novel, all oral therapeutic approach for treating RRMM patients."

Clinical • P1 data • Graft versus Host Disease • Hematological Malignancies • Immunology • Multiple Myeloma • Myelofibrosis • Oncology • Polycythemia Vera

Long-Term Effect of Oral Methylprednisolone on Kidney Outcomes in Patients with IgAN: TESTING-ON, a Post-Trial Observational Study (KIDNEY WEEK 2025) - P | "The reduction of time averaged proteinuria among those who received methylprednisolone was no longer evident whilst the between group differences in annual eGFR slope remained significant throughout the post-trial period. Conclusion The beneficial effect of oral methylprednisolone on kidney failure and related outcomes in individuals with high-risk IgA nephropathy persisted out to a median follow-up of 6.4 years."

Clinical • Late-breaking abstract • Observational data • Glomerulonephritis • IgA Nephropathy

Retinoic Acid plus Hydroxychloroquine Sulfate and Methylprednisolone in Patients with Erosive Oral Lichen Planus: A Randomized and Controlled Clinical Trial (ChiCTR) - P4 | N=146 | Not yet recruiting | Sponsor: Shanghai Ninth People's Hospital， Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital， Shanghai JiaoTong University

New P4 trial • Dermatology • Dermatopathology • Lichen Planus

Fever of Unknown Origin Secondary to Necrotizing Hepatic Granulomas: A Rare Case of Idiopathic Granulomatous Hepatitis (ACG 2025) - "Despite initial treatment with posaconazole, symptoms worsened...Because of ferritin and IL-2 elevation, colchicine was trialed but was complicated by influenza-related fevers. She was discharged on oral 32mg methylprednisolone once daily, trimethoprim/sulfamethoxazole once daily for prophylaxis, and furosemide for hypervolemia...MR abdomen demonstrating numerous bilobar ill-defined peripherally enhancing and diffusion restricting liver lesions. Conglomerate lesion at the dome measuring 4.9 x 4 cm viewable in this cut."

Clinical • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Influenza • Respiratory Diseases • Rheumatology • Sarcoidosis • Tuberculosis • IL2

Analysis of the Clinical Efficacy of Vitamin D in the Treatment of Sudden Deafness (ChiCTR) - P=N/A | N=101 | Recruiting | Sponsor: The First People's Hospital of Yinchuan; The First People's Hospital of Yinchuan

New trial • Otorhinolaryngology